Millennium Pharmaceuticals Limited

Sunesis Pharmaceuticals, Inc.

Merck + Co., Inc.

Knopp Biosciences, LLC

Biogen, Incorporated

Biogen Idec Ma Inc.

Weirong Chen

Hairuo Peng

William F Kiesman

Erwin Irdam

Benjamin Lane

Gnanasambandam Kumaravel

Alexey Alexandrovich Lugovskoy

Hiroko Tanaka

Zhili Xin

John Howard Jones

Bing Guan

Noel Aaron Powell

Brian Raimundo

Michael J Humora

Jeffrey Vessels

Jennifer Cossrow

Thomas Wynn

Adam Littke

Lloyd Franklin

Sander G Mills

Jeffrey John Hale

Christopher L Lynch

Feng Xu

Richard D Tillyer

Lushi Tan

Cheng Yi Chen

Paul O'Shea

Daw-long Albert Kwok

Zhen Li

Daw-Iong Albert Kwok

William E Neway, Iii

Tamera L Mack

Wenli Liang

Donald G Walker

Philippe Dagneau

Daniel B Patience

Suzanne M Opalka

Daw-Long A Kwok

Vinny Couming

Lioyd Franklin

The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.

Process for preparing alpha-carboxamide pyrrolidine derivatives

The present invention is related to an improved process for the preparation of amino-substituted 4,5,6,7-tetrahydrobenzothiazole compounds of formula I, such as the compound 2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention further relates to an improved synthesis of (R)-2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention also relates to the methods and intermediates associated with the synthetic process.

Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds

The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, L, L, Cy, and Cyare as defined as set forth in the specification.

Substituted pyrimidines for inhibiting Raf kinase activity

The present disclosure provides compounds having Formula II-vi-a: wherein Cy, Cy, and Aare defined as set forth in the specification. These compounds are synthetic intermediates used to prepare inhibitors of Raf protein kinase.

Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Compounds useful as Raf kinase inhibitors

The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists

Synthesis of ketosulfone esters

Growing community of inventors

Waltham, MA, United States of America

Weirong Chen